Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLYG8824A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose-Escalation Stage | EXPERIMENTAL | Participants will be assigned sequentially to escalating doses of BLYG8824A, up to the maximum tolerated dose (MTD). |
| Dose-Expansion Stage | EXPERIMENTAL | Once dose escalation is completed and the MTD (or MAD) has been identified, a recommended expansion dose will be proposed for the dose-expansion stage of the trial. |
| Name | Type | Description |
|---|---|---|
| BLYG8824A | DRUG | BLYG8824A will be administered at a flat dose independent of body weight. |
Inclusion Criteria: * ECOG performance status of 0 or 1 * Life expectancy of at least 12 weeks * Histologically or cytologically documented invasive CRC: incurable, unresectable, locally advanced or metastatic CRC previously treated with multimodality therapy or mCRC * Locally advanced or metastati...
Top 20 of 77 competitors
BLYG8824A is an investigational small molecule being studied for the treatment of colorectal cancer. It is being evaluated in patients with locally advanced or metastatic colorectal cancer. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
BLYG8824A is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
BLYG8824A is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory agencies for commercial use. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
BLYG8824A has been studied in one clinical trial registered as NCT04468607, titled "A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer." This Phase 1 trial enrolled 46 participants and was conducted in the United States, Australia, and Spain. The trial has been completed.
BLYG8824A is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial evaluated the drug in patients with colorectal cancer, but further clinical studies would be needed before any regulatory approval could be considered.